Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00281710

Enrollment

Registered

2006-01-25

Start date

2005-10-31

Completion date

2007-02-28

Last updated

2008-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

AQP-2, Methylprednisolone, Urinary concentrating ability

Brief summary

We wanted to test the hypotheses that methylprednisolone up regulates u-AQP-2 in fasting healthy humans

Interventions

DRUGMethylprednisolone

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Masking

SINGLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* (1) Genders; both mal and female * (2) Age; 18- 65 years old * (3) BMI; below 30 * (4) Females had to bee in oral contraceptive treatment

Exclusion criteria

* (1) Clinical signs or history of disease in the heart, lungs, kidneys or endocrine organs * (2) Abnormal laboratory test (blood haemoglobin, white cell count, platelets, plasma sodium, plasma potassium, plasma creatinine, plasma albumin, plasma bilirubin, plasma alanine aminotransferase, plasma cholesterol and blood glucose) * (3) Albuminuria or glucosuria * (4) Cancer * (5) Arterial hypertension * (6) Alcohol abuse * (7) Use of tobacco * (8) Medical treatment, except oral contraceptives * (9) Pregnancy or breast feeding * (10) Medicine abuse * (11) Donation of blood less than 1 month before the study.

Design outcomes

Primary

Measure	Time frame
u-AQP-2	—
FeNa+	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026